These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. C-reactive protein in cardiovascular risk prediction. Zooming in and zooming out. Maseri A Ital Heart J; 2001 Mar; 2(3):155-6. PubMed ID: 11305525 [No Abstract] [Full Text] [Related]
7. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Ridker PM Circulation; 2003 Jan; 107(3):363-9. PubMed ID: 12551853 [No Abstract] [Full Text] [Related]
8. Biomarkers. Screening for C-reactive protein in CVD prediction. Peters SA; Visseren FL; Grobbee DE Nat Rev Cardiol; 2013 Jan; 10(1):12-4. PubMed ID: 23165068 [TBL] [Abstract][Full Text] [Related]
9. Letter regarding article by Ridker et al, "Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?". Lloyd-Jones DM; Greenland P Circulation; 2004 Dec; 110(24):e532. PubMed ID: 15596555 [No Abstract] [Full Text] [Related]
10. Metabolic syndrome: a marker of patients at high cardiovascular risk. Lau DC; Yan H; Dhillon B Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):85B-90B. PubMed ID: 16498518 [TBL] [Abstract][Full Text] [Related]
11. [The prevalence of metabolic syndrome in middle-aged in Kaunas population]. Gustiene O; Slapikas R; Klumbiene J; Sakalauskiene G; Kubilius R; Bagdzeviciūte S; Zaliūnas R Medicina (Kaunas); 2005; 41(10):867-76. PubMed ID: 16272835 [TBL] [Abstract][Full Text] [Related]
12. High sensitive C-reactive protein (hsCRP), cardiovascular events and mortality in the aged: a prospective 9-year follow-up study. Kuoppamäki M; Salminen M; Vahlberg T; Irjala K; Kivelä SL; Räihä I Arch Gerontol Geriatr; 2015; 60(1):112-7. PubMed ID: 25456891 [TBL] [Abstract][Full Text] [Related]
13. The metabolic syndrome and the risk of thrombosis. Dentali F; Romualdi E; Ageno W Haematologica; 2007 Mar; 92(3):297-9. PubMed ID: 17339177 [No Abstract] [Full Text] [Related]
14. Ultrasound-assessed visceral fat and associations with glucose homeostasis and cardiovascular risk in clinical practice. Bellan M; Menegatti M; Ferrari C; Carnevale Schianca GP; Pirisi M Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):610-617. PubMed ID: 29656956 [TBL] [Abstract][Full Text] [Related]
15. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Ridker PM; Wilson PW; Grundy SM Circulation; 2004 Jun; 109(23):2818-25. PubMed ID: 15197153 [TBL] [Abstract][Full Text] [Related]
16. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Guijarro C Circulation; 2001 Nov; 104(22):E127. PubMed ID: 11723039 [No Abstract] [Full Text] [Related]
17. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Devaraj S; Valleggi S; Siegel D; Jialal I Curr Atheroscler Rep; 2010 Mar; 12(2):110-8. PubMed ID: 20425246 [TBL] [Abstract][Full Text] [Related]
18. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Torres JL; Ridker PM Curr Opin Cardiol; 2003 Nov; 18(6):471-8. PubMed ID: 14597888 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular biomarkers: added value with an integrated approach? Koenig W Circulation; 2007 Jul; 116(1):3-5. PubMed ID: 17606853 [No Abstract] [Full Text] [Related]
20. [Predictive value C-reactive protein assessment level in women with arterial hypertension]. Andrievskaia EM; Ivleva AIa; Minina ES; Lagutina OE Kardiologiia; 2011; 51(8):32-8. PubMed ID: 21942956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]